FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2514713598> ?p ?o ?g. }

• W2514713598 endingPage "98" @default.
• W2514713598 startingPage "89" @default.
• W2514713598 abstract "Fibroblast activation protein α (FAPα) is expressed in cancer-associated fibroblasts (CAFs), which are the main type of cells in the tumor microenvironment. CAFs exert immunosuppressive activity, which can weaken the effects of cancer immunotherapy and mainly account for poor outcomes with therapeutic vaccines. To better target and destroy CAFs, a FAPα vaccine using a modified vaccinia ankara (MVA) vector was constructed and used with a DNA vaccine reported in our previous work for heterologous prime-boost immunizations in mice. This strategy to generate anti-tumor immunity partly reduced 4T1 tumor growth through producing FAPα-specific cytotoxic T lymphocyte responses in a preventive model, but the effect required improvement. Combining the FAPα-based cancer vaccines (CpVR-FAP/MVA-FAP) with cyclophosphamide (CY), which can be used not only as a chemotherapeutic but also an immunomodulatory agent to promote a shift from immunosuppression to immunopotentiation, resulted in markedly enhanced tumor growth inhibition compared with the CpVR-FAP/MVA-FAP group. This strategy achieved synergistic effects in a therapeutic model by improving the tumor inhibition rate by 2.5-fold (90.2%), significantly enhancing cellular immunity and prolonging the survival of 4T1 tumor-bearing mice by 35% compared with the PBS group. Furthermore, CAFs, stromal factors and immunosuppressive factors such as IL-10 and Tregs were also markedly decreased by the CY combination. These results indicated that FAPα-targeted MVA boosting in combination with CY is an effective approach to improving specific anti-tumor immune responses through overcoming immunosuppression. This study may offer important advances in research on clinical cancer immunotherapies by modulating immunosuppressive factors." @default.
• W2514713598 created "2016-09-16" @default.
• W2514713598 creator A5002843546 @default.
• W2514713598 creator A5008058822 @default.
• W2514713598 creator A5011157307 @default.
• W2514713598 creator A5021231816 @default.
• W2514713598 creator A5029063882 @default.
• W2514713598 creator A5032109161 @default.
• W2514713598 creator A5032257574 @default.
• W2514713598 creator A5037458498 @default.
• W2514713598 creator A5054493580 @default.
• W2514713598 creator A5071959801 @default.
• W2514713598 creator A5074673516 @default.
• W2514713598 creator A5075115724 @default.
• W2514713598 creator A5085796521 @default.
• W2514713598 creator A5086632320 @default.
• W2514713598 date "2016-12-01" @default.
• W2514713598 modified "2023-10-16" @default.
• W2514713598 title "Improvement of anti-tumor immunity of fibroblast activation protein α based vaccines by combination with cyclophosphamide in a murine model of breast cancer" @default.
• W2514713598 cites W1492166511 @default.
• W2514713598 cites W1530046839 @default.
• W2514713598 cites W1952391983 @default.
• W2514713598 cites W1964080141 @default.
• W2514713598 cites W1964266353 @default.
• W2514713598 cites W1968893400 @default.
• W2514713598 cites W1978012785 @default.
• W2514713598 cites W1982478444 @default.
• W2514713598 cites W1989025666 @default.
• W2514713598 cites W1995481385 @default.
• W2514713598 cites W2002145465 @default.
• W2514713598 cites W2002689409 @default.
• W2514713598 cites W2006405806 @default.
• W2514713598 cites W2015616022 @default.
• W2514713598 cites W2038665605 @default.
• W2514713598 cites W2044835625 @default.
• W2514713598 cites W2048253455 @default.
• W2514713598 cites W2048488403 @default.
• W2514713598 cites W2060469376 @default.
• W2514713598 cites W2062809449 @default.
• W2514713598 cites W2073647827 @default.
• W2514713598 cites W2082830752 @default.
• W2514713598 cites W2084355281 @default.
• W2514713598 cites W2085121865 @default.
• W2514713598 cites W2085138770 @default.
• W2514713598 cites W2090287101 @default.
• W2514713598 cites W2092018061 @default.
• W2514713598 cites W2100158834 @default.
• W2514713598 cites W2101037339 @default.
• W2514713598 cites W2114973326 @default.
• W2514713598 cites W2124154627 @default.
• W2514713598 cites W2144066540 @default.
• W2514713598 cites W2144325011 @default.
• W2514713598 cites W2146646005 @default.
• W2514713598 cites W2159465958 @default.
• W2514713598 cites W2165328065 @default.
• W2514713598 cites W2209812019 @default.
• W2514713598 cites W2318150125 @default.
• W2514713598 cites W2331553063 @default.
• W2514713598 doi "https://doi.org/10.1016/j.cellimm.2016.08.006" @default.
• W2514713598 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27545090" @default.
• W2514713598 hasPublicationYear "2016" @default.
• W2514713598 type Work @default.
• W2514713598 sameAs 2514713598 @default.
• W2514713598 citedByCount "20" @default.
• W2514713598 countsByYear W25147135982017 @default.
• W2514713598 countsByYear W25147135982018 @default.
• W2514713598 countsByYear W25147135982019 @default.
• W2514713598 countsByYear W25147135982020 @default.
• W2514713598 countsByYear W25147135982021 @default.
• W2514713598 countsByYear W25147135982022 @default.
• W2514713598 countsByYear W25147135982023 @default.
• W2514713598 crossrefType "journal-article" @default.
• W2514713598 hasAuthorship W2514713598A5002843546 @default.
• W2514713598 hasAuthorship W2514713598A5008058822 @default.
• W2514713598 hasAuthorship W2514713598A5011157307 @default.
• W2514713598 hasAuthorship W2514713598A5021231816 @default.
• W2514713598 hasAuthorship W2514713598A5029063882 @default.
• W2514713598 hasAuthorship W2514713598A5032109161 @default.
• W2514713598 hasAuthorship W2514713598A5032257574 @default.
• W2514713598 hasAuthorship W2514713598A5037458498 @default.
• W2514713598 hasAuthorship W2514713598A5054493580 @default.
• W2514713598 hasAuthorship W2514713598A5071959801 @default.
• W2514713598 hasAuthorship W2514713598A5074673516 @default.
• W2514713598 hasAuthorship W2514713598A5075115724 @default.
• W2514713598 hasAuthorship W2514713598A5085796521 @default.
• W2514713598 hasAuthorship W2514713598A5086632320 @default.
• W2514713598 hasConcept C111798993 @default.
• W2514713598 hasConcept C121608353 @default.
• W2514713598 hasConcept C126322002 @default.
• W2514713598 hasConcept C154317977 @default.
• W2514713598 hasConcept C16930146 @default.
• W2514713598 hasConcept C202751555 @default.
• W2514713598 hasConcept C203014093 @default.
• W2514713598 hasConcept C2776107976 @default.
• W2514713598 hasConcept C2776694085 @default.
• W2514713598 hasConcept C2776755627 @default.
• W2514713598 hasConcept C2777701055 @default.
• W2514713598 hasConcept C2780252810 @default.

• next